Ipsen News

Aktie
WKN:  A0ESMG ISIN:  FR0010259150 US-Symbol:  IPSEF Branche:  Pharmazeutika Land:  Frankreich
153,10 €
+3,20 €
+2,13%
27.03.26
Depot/Watchlist
Marktkapitalisierung *
10,01 Mrd. €
Streubesitz
27,41%
KGV
26,60
Dividende
1,40 EUR
Dividendenrendite
1,18%
Nachhaltigkeits-Score
68 %
Index-Zuordnung
-

Ipsen News

24.07.25 - GlobeNewswire
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of ...
23.07.25 - GlobeNewswire
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive ...
20.06.25 - GlobeNewswire
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade ...
31.05.25 - GlobeNewswire
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study ...
07.05.25 - GlobeNewswire
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
Additional late-​breaking data suggests up to twice as many patients treated with IQIRVO ® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 ...
06.05.25 - GlobeNewswire
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-​driven biopharmaceutical company, announced today the appointment of Laura Réveillon, ...
24.04.25 - GlobeNewswire
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
Elafibranor showed a favorable safety profile and demonstrated dose-​dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no ...
16.04.25 - GlobeNewswire
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER 1 , or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib ...
19.03.25 - GlobeNewswire
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s
12.03.25 - GlobeNewswire
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
PARIS, FRANCE, March 12 th , 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-​driven company, announced today the appointment of Olivia Brown as, EVP, Global ...
13.02.25 - GlobeNewswire
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
FY 2024 total sales growth of 9.9% at CER 1 , or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare ...
07.12.24 - Börse-Global
Ipsen Aktie: Perspektiven für die Zukunft
Die französische Pharmafirma Ipsen verzeichnet eine bedeutende Änderung in ihrer Aktionärsstruktur. Parvus Asset Management Europe Limited hat kürzlich die 5-Prozent-...
03.12.24 - GlobeNewswire
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-​clinical novel T cell engager (TCE) with first-​in-class potential BMX-502 is a ...
18.11.24 - GlobeNewswire
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Ipsen presents 3 late-​breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext ...
15.11.24 - GlobeNewswire
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-​breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the ...
23.10.24 - GlobeNewswire
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​care biopharmaceutical company, today presents its performance for the year to date and ...
14.10.24 - GlobeNewswire
Ipsen receives its second Shingo Prize for operational excellence
Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patients Ipsen’s first Shingo Prize was received by its production site in ...
23.09.24 - GlobeNewswire
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Kayfanda ® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing ...
20.09.24 - GlobeNewswire
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo ® (elafibranor), first-​in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease ...
16.09.24 - GlobeNewswire
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ® (cabozantinib) versus placebo in advanced ...

Newssuche

Videos

newspaper
23.03.26 +7,97%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »